The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum
Reference (39)
- et al.
α-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation
Brain Res.
(1990) - et al.
α-Methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex
Brain Res.
(1986) - et al.
Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine
Brain Res.
(1992) - et al.
TheN-methyl-d-aspartate antagonist MK-801 protects serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine andp-chloroamphetamine
Brain Res.
(1992) - et al.
The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole
Neuropharmacology
(1992) - et al.
Neuronal degeneration in rat brain induced by 6-hydroxydopamine; a histological and biochemical study
Brain Res.
(1972) - et al.
Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog
Eur. J. Pharmacol.
(1989) - et al.
Neurochemical, endocrine and immunological response to stress in young and old Fisher 344 male rats
Neurobiol. Aging
(1990) - et al.
The effects of monoamine uptake inhibitors and methamphethamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat
Brain Res.
(1990) - et al.
Dopamine uptake inhibitors block long-term neurotoxic effects of methamphethamine upon dopaminergic neurons
Brain Res.
(1990)
Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment
Brain Res.
A glutamergic corticostriatal path?
Brain Res.
MK-801, a non-competitive antagonist of NMDA receptor, prevents methamphetamine-induced decrease of striatal dopamine uptake sites in the rat striatum
Neurosci. Lett.
Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine
Brain Res.
Multiple methamphetamine injections induced marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity
Brain Res.
In vivo release of endogenous glutamate and aspartate in the rat striatum during stimulation of the cortex
Neuroscience
Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum
Dev. Brain Res.
Histological and ultrastructural evidence thatd-amphetamine causes degeneration in neostriatum and frontal cortex of rats
Brain Res.
Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid
Eur. J. Pharmacol.
Cited by (71)
Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine
2021, Experimental NeurologyCitation Excerpt :We found that PKO rats are somewhat resistant to METH neurotoxicity in the striatum. At the molecular level, METH neurotoxicity to DAergic and 5-HTergic terminals in the striatum is manifested by persistent (lasting after METH cessation) reductions in all DAergic and 5-HTergic markers (e.g. DA, 5-HT and their metabolites) (Broening et al., 1997; Harvey et al., 2000; Preston et al., 1985; Sonsalla et al., 1986; Wagner et al., 1980), morphological and structural abnormalities (Lorez, 1981; Ricaurte et al., 1982; Sharma and Kiyatkin, 2009) as well as microglial activation and gliosis (Pu et al., 1994; Thomas et al., 2004). In rodents, binge METH exposure typically results in more severe or longer-lasting effects than a chronic exposure of comparable cumulative dose (Keller et al., 2011; Kesby et al., 2018; Moszczynska et al., 1998), suggesting development of tolerance to METH toxic effects.
Abuse potential and toxicity of the synthetic cathinones (i.e., “Bath salts”)
2020, Neuroscience and Biobehavioral ReviewsAstroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis
2018, Progress in Neuro-Psychopharmacology and Biological PsychiatryA peptide disrupting the D2R-DAT interaction protects against dopamine neurotoxicity
2017, Experimental NeurologyCitation Excerpt :D2R and DAT, two important presynaptic proteins that regulate dopamine concentration in the synapse, have been found to play important roles in dopamine neurotoxicity. D2R antagonists and DAT blockers were shown to attenuate METH-induced degeneration of dopaminergic terminals thus implicating both D2R as well as DAT in mediating the neurotoxicity of the drug (Albers and Sonsalla, 1995; Eisch and Marshall, 1998; Hadlock et al., 2010; Marek et al., 1990; Pu et al., 1994). METH is initially taken up to dopaminergic terminals via DAT.
Mephedrone: An Overview of Its Neurotoxic Potential
2016, Neuropathology of Drug Addictions and Substance Misuse
- **
Current address: the Neuropharmacological Drug Products Branch, Center for Drug Safety, US Food and Drug Administration; 5600 Fishers Lane, Rockville, MD 20857, USA.